Okeiro Secures €10 Million to Advance AI-Driven Precision Medicine Platform for Transplantation and Chronic Diseases
• Okeiro (formerly Predict4Health) has raised €10 million in funding led by Alven, Forepont Capital Partners, and Red River West to expand its AI-powered clinical decision support platform internationally.
• The company's proprietary iBox algorithm, recognized as a surrogate endpoint by FDA and EMA, enables early prediction of transplant rejection and has already been implemented in leading French transplant centers.
• Okeiro is conducting a multi-center randomized clinical trial across 16 hospitals in 6 countries to validate its technology's effectiveness compared to standard care protocols.
Vir Biotechnology's Combination Therapy Shows Promise in Hepatitis Delta Trial
• Vir Biotechnology's tobevibart and elebsiran combination achieved 100% virologic suppression in chronic hepatitis delta (CHD) patients at Week 24, sustained through Week 60.
• HDV RNA was undetectable in 41% of participants at Week 24, increasing to 80% by Week 60, indicating potential viral clearance with the combination therapy.
• The combination therapy was well-tolerated, with no treatment-related severe adverse events, discontinuations, or ALT flares reported during the trial.
• Vir Biotechnology plans to initiate a Phase 3 registrational program (ECLIPSE) in the first half of 2025 to further evaluate the combination for CHD treatment.
© Copyright 2025. All Rights Reserved by MedPath